Insilico Medicine Joins HKEX Tech 100 Index

The Hong Kong Exchanges and Clearing (HKEX) added the clinical-stage firm to its benchmark index following recent methodology updates designed to capture emerging AI value chains. This inclusion is poised to increase trading liquidity and draw capital from Mainland Chinese investors via Southbound Stock Connect, further cementing the company's position among major tech-focused portfolios.

Insilico's financial momentum mirrors its operational output. The company reported an adjusted net profit exceeding $51 million for the first half of 2026, bolstered by high-value collaborations with partners including Eli Lilly, Servier, and Takeda. Total contract value for deals announced this year has reached approximately $7.3 billion. Beyond the balance sheet, the firm set a record in pipeline productivity by nominating nine development candidates in nine months, led by Rentosertib, the world's first generative AI-discovered drug now in Phase III trials for idiopathic pulmonary fibrosis.